|
1
|
Hu BR, Fairey AS, Madhav A, Yang D, Li M,
Groshen S, Stephens C, Kim PH, Virk N, Wang L, et al: AXIN2
expression predicts prostate cancer recurrence and regulates
invasion and tumor growth. Prostate. 76:597–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li HY, Jin N, Han YP and Jin XF: Pathway
crosstalk analysis in prostate cancer based on protein-protein
network data. Neoplasma. 64:22–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stephenson AJ, Scardino PT, Eastham JA,
Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA and Kattan
MW: Postoperative nomogram predicting the 10-year probability of
prostate cancer recurrence after radical prostatectomy. J Clin
Oncol. 23:7005–7012. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu BR, Fairey AS, Madhav A, Yang D, Li M,
Groshen S, Stephens C, Kim PH, Virk N, Wang L, et al: AXIN2
expression predicts prostate cancer recurrence and regulates
invasion and tumor growth. Prostate. 76:597–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hao J, Chiang YT, Gout PW and Wang Y:
Elevated XPO6 expression as a potential prognostic biomarker for
prostate cancer recurrence. Front Biosci (Schol Ed). 8:44–55. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choudhury AD, Eeles R, Freedland SJ,
Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL and Visakorpi T:
The role of genetic markers in the management of prostate cancer.
Eur Urol. 62:577–587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heidegger I, Höfer J, Luger M, Pichler R,
Klocker H, Horninger W, Steiner E, Jochberger S and Culig Z: Is
Eotaxin-1 a serum and urinary biomarker for prostate cancer
detection and recurrence? Prostate. 75:1904–1909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stephenson AJ, Smith A, Kattan MW,
Satagopan J, Reuter VE, Scardino PT and Gerald WL: Integration of
gene expression profiling and clinical variables to predict
prostate carcinoma recurrence after radical prostatectomy. Cancer.
104:290–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun Y and Goodison S: Optimizing molecular
signatures for predicting prostate cancer recurrence. Prostate.
69:1119–1127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gene Ontology Consortium, . The Gene
Ontology (GO) project in 2006. Nucleic Acids Res. 34(Database
issue): D322–D326. 2006.PubMed/NCBI
|
|
11
|
Kanehisa M and Goto S.: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thoma C: Prostate cancer: The genomics of
localized disease. Nat Rev Urol. 14:652017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khor LY, Bae K, Al-Saleem T, Hammond EH,
Grignon DJ, Sause WT, Pilepich MV, Okunieff PP, Sandler HM and
Pollack A: Protein kinase A RI-alpha predicts for prostate cancer
outcome: analysis of radiation therapy oncology group trial 86–10.
Int J Radiat Oncol Biol Phys. 71:1309–1315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Govindan R: The Washington Manual of
Oncology. 2nd. Lippincott Williams and Wilkins; Philadelphia:
2008
|
|
15
|
Merkle D and Hoffmann R: Roles of cAMP and
cAMP-dependent protein kinase in the progression of prostate
cancer: Cross-talk with the androgen receptor. Cell Signal.
23:507–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rahrmann EP, Collier LS, Knutson TP, Doyal
ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz
M, et al: Identification of PDE4D as a proliferation promoting
factor in prostate cancer using a Sleeping Beauty transposon-based
somatic mutagenesis screen. Cancer Res. 69:4388–4397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Henderson DJ, Byrne A, Dulla K, Jenster G,
Hoffmann R, Baillie GS and Houslay MD: The cAMP
phosphodiesterase-4D7 (PDE4D7) is downregulated in
androgen-independent prostate cancer cells and mediates
proliferation by compartmentalising cAMP at the plasma membrane of
VCaP prostate cancer cells. Br J Cancer. 110:1278–1287. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Böttcher R, Henderson DJ, Dulla K, van
Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders
GJ, Baillie GS, et al: Human phosphodiesterase 4D7 (PDE4D7)
expression is increased in TMPRSS2-ERG-positive primary prostate
cancer and independently adds to a reduced risk of post-surgical
disease progression. Br J Cancer. 113:1502–1511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Böttcher R, Dulla K, van Strijp D, Dits N,
Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G and
Hoffmann R: Human PDE4D isoform composition is deregulated in
primary prostate cancer and indicative for disease progression and
development of distant metastases. Oncotarget. 7:70669–70684.
2016.PubMed/NCBI
|
|
20
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guan M, Fousek K and Chow WA: Nelfinavir
inhibits regulated intramembrane proteolysis of sterol regulatory
element binding protein-1 and activating transcription factor 6 in
castration-resistant prostate cancer. FEBS J. 279:2399–2411. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bach LA and Hale LJ: Insulin-like growth
factors and kidney disease. Am J Kidney Dis. 65:327–336. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shanmugalingam T, Bosco C, Ridley AJ and
Van Hemelrijck M: Is there a role for IGF-1 in the development of
second primary cancers? Cancer Med. 5:3353–3367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao Y, Nimptsch K, Shui IM, Platz EA, Wu
K, Pollak MN, Kenfield SA, Stampfer MJ and Giovannucci EL:
Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.
Int J Cancer. 136:2418–2426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dunn SE, Kari FW, French J, Leininger JR,
Travlos G, Wilson R and Barrett JC: Dietary restriction reduces
insulin-like growth factor I levels, which modulates apoptosis,
cell proliferation, and tumor progression in p53-deficient mice.
Cancer Res. 57:4667–4672. 1997.PubMed/NCBI
|
|
26
|
McKeown BT and Hurta RA: Magnolol affects
expression of IGF-1 and associated binding proteins in human
prostate cancer cells in vitro. Anticancer Res. 34:6333–6338.
2014.PubMed/NCBI
|
|
27
|
Shukla S, MacLennan GT, Fu P and Gupta S:
Apigenin attenuates insulin-like growth factor-I signaling in an
autochthonous mouse prostate cancer model. Pharm Res. 29:1506–2617.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsuchiya N, Narita S, Inoue T, Saito M,
Numakura K, Huang M, Hatakeyama S, Satoh S, Saito S, Ohyama C, et
al: Insulin-like growth factor-1 genotypes and haplotypes influence
the survival of prostate cancer patients with bone metastasis at
initial diagnosis. BMC Cancer. 13:1502013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mehta PB, Jenkins BL, McCarthy L, Thilak
L, Robson CN, Neal DE and Leung HY: MEK5 overexpression is
associated with metastatic prostate cancer, and stimulates
proliferation, MMP-9 expression and invasion. Oncogene.
22:1381–1389. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma W, He X, Zhang H, Liu T, Feng X and
Zhou Q: Down-regulation of receptor-tyrosine-kinase-like orphan
receptor 1 suppresses cell growth and enhances apoptosis in human
colorectal carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
32:655–665. 2016.(In Chinese). PubMed/NCBI
|
|
31
|
Hojjat-Farsangi M, Moshfegh A,
Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A and Mellstedt
H: The receptor tyrosine kinase ROR1-an oncofetal antigen for
targeted cancer therapy. Semin Cancer Biol. 29:21–31. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oshima T, Yoshihara K, Aoyama T, Hasegawa
S, Sato T, Yamamoto N, Akito N, Shiozawa M, Yoshikawa T, Numata K,
et al: Relation of INHBA gene expression to outcomes in gastric
cancer after curative surgery. Anticancer Res. 34:2303–2309.
2014.PubMed/NCBI
|
|
33
|
Lee HY, Li CC, Huang CN, Li WM, Yeh HC, Ke
HL, Yang KF, Liang PI, Li CF and Wu WJ: INHBA overexpression
indicates poor prognosis in urothelial carcinoma of urinary bladder
and upper tract. J Surg Oncol. 111:414–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim
H, Nishikawa S, Konno M, Kawamoto K, Haraguchi N, Takemasa I, et
al: Significance of INHBA expression in human colorectal cancer.
Oncol Rep. 30:2903–2908. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tuscano JM, Kato J, Pearson D, Xiong C,
Newell L, Ma Y, Gandara DR and O'Donnell RT: CD22 antigen is
broadly expressed on lung cancer cells and is a target for
antibody-based therapy. Cancer Res. 72:5556–5565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pop LM, Barman S, Shao C, Poe JC, Venturi
GM, Shelton JM, Pop IV, Gerber DE, Girard L, Liu XY, et al: A
reevaluation of CD22 expression in human lung cancer. Cancer Res.
74:263–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
